MIMEDX Appoints Matt Notarianni as Head of Investor Relations
04 Outubro 2022 - 9:00AM
MiMedx Group, Inc. (NASDAQ: MDXG) (“MIMEDX” or the “Company”), a
transformational placental biologics company, today announced the
appointment of Matt Notarianni as Head of Investor Relations (IR),
effective immediately. Mr. Notarianni joins MIMEDX with over 15
years of healthcare-focused Wall Street and IR experience, most
recently serving as head of IR for Cerus Corporation.
“I am delighted to welcome Matt to MIMEDX,”
stated K. Todd Newton, MIMEDX interim Chief Executive Officer. “The
breadth of Matt’s experience in healthcare-focused financial
services, IR and strategy roles make him a great fit to amplify the
MIMEDX story to the investment community. I look forward to working
with Matt to continue to evolve our IR strategy and heighten our
engagement level with current and prospective investors and
analysts.”
“I am thrilled to join MIMEDX at this critical
time at the Company,” Mr. Notarianni stated. “As a pioneer and the
leader in placental biologics, MIMEDX has a strong business with a
number of compelling growth opportunities ahead. I look forward to
working with the management team and Board to help realize these
opportunities and communicate the Company’s progress with the
investment community.”
Jack Howarth, MIMEDX Senior Vice President of
Investor Relations, will continue to support the MIMEDX IR function
until his planned retirement at the end of this year.
“On behalf of the entire MIMEDX team, I want to
thank Jack for his many contributions to the Company over the
years,” continued Mr. Newton. “With a career spanning over four
decades, we wish Jack a wonderful retirement.”
Prior to his role at Cerus, Mr. Notarianni was
at Immucor, Inc. from 2012-2021, serving most recently as Senior
Director, Corporate Development & External Communications. He
began his career as an equity research analyst at Robert W. Baird
& Co. covering the life science tools and diagnostics space.
Mr. Notarianni received his B.S. in Business Administration from
Marquette University.
About MIMEDX
MIMEDX is a transformational placental biologics
company, developing and distributing placental tissue allografts
with patent-protected, proprietary processes for multiple sectors
of healthcare. As a pioneer in placental tissue engineering, we
have both a commercial business, focused on addressing the needs of
patients with acute and chronic non-healing wounds, and a promising
late-stage pipeline targeted at decreasing pain and improving
function for patients with degenerative musculoskeletal conditions.
We derive our products from human placental tissues and process
these tissues using our proprietary methods, including the PURION®
process. We employ Current Good Tissue Practices, Current Good
Manufacturing Practices, and terminal sterilization to produce our
allografts. MIMEDX has supplied over two million allografts,
through both direct and consignment shipments. For additional
information, please visit www.mimedx.com.
Contact:
Matt NotarianniInvestor Relations470-304-7291
mnotarianni@mimedx.com
MiMedx (NASDAQ:MDXG)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
MiMedx (NASDAQ:MDXG)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024